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Objective: To investigate the feasibility and determine the
recommended pre-operative intensity-modulated radiother-
apy (IMRT) dose of extended-field chemoradiation along
with simultaneous integrated boost (SIB) dose escalation.
Methods: A radiation dose of 40Gy over 4 weeks,
2Gy/fraction, was delivered to the tumour and the lym-
phatic drainage (planning target volume, PTV3), which
encompassed a volume larger than standard (common
iliac lymphatic area up to its apex, in front of the L3
vertebra), concurrently with chemotherapy (cisplatin and
5-fluorouracil). Radiation dose was escalated to the pelvis
(PTV2) and to the macroscopic disease (PTV1) with the
SIB-IMRT strategy. Three dose levels were planned: Level 1
(PTV3: 40/2Gy; PTV2: 40/2Gy; PTV1: 45/2.25Gy), Level 2
(PTV3: 40/2Gy; PTV2: 45/2.25Gy; PTV1: 45/2.25Gy) and
Level 3 (PTV3: 40/2Gy; PTV2: 45/2.25Gy; PTV1: 50/
2.5Gy). All treatments were delivered in 20 fractions. Pa-
tients were treated in cohorts of between three and six per
group using a Phase I study design. The recommended dose
was exceeded if two of the six patients in a cohort expe-
rienced dose-limiting toxicity within 3months from treatment.
Results: 19 patients [median age: 46 years; The Interna-
tional Federation of Gynecology and Obstetrics (FIGO)
stage IB2: 3, IIB: 10, IIIA–IIIB: 6] were enrolled. Median
follow-up was 24 months (9–60 months). The most com-
mon grade 3/4 toxicity was gastrointestinal (GI) (di-
arrhoea, mucous discharge, rectal/abdominal pain). At
Levels 1 and 2, only one grade 3 GI toxicity per level was
recorded, whereas at Level 3, two grade 3 GI toxicities
(diarrhoea, emesis and nausea) were recorded.
Conclusion: The SIB-IMRT technique was found to be
feasible and safe at the recommended doses of 45Gy to
PTV1 and PTV2 and 40Gy to PTV3 in the pre-operative
treatment of patients with locally advanced cervical
cancer. Unfortunately, this complex technique was unable
to safely escalate dose beyond levels already achieved
with three-dimensional conformal radiotherapy tech-
nique given acute GI toxicity.
Advances in knowledge: A Phase I radiotherapy dose-
escalation trial with SIB-IMRT technique is proposed in
cervical cancer. This complex technique is feasible and safe
at the recommended doses.
INTRODUCTION
Even with the advent of exclusive chemoradiation [CT/
radiotherapy (RT)] as the standard treatment for locally ad-
vanced cervical cancer (LACC) since 1999,1 the 5-year overall
survival (OS) still remains around 70% in this subset of
patients. It is well known that radical surgery (RS) following
CT/RT is not a worldwide standard strategy. Nevertheless,
investigational approaches that use completion surgery after
CT/RT or chemotherapy have also been investigated with the
aim to remove potentially radioresistant and chemoresistant
tumour foci, evaluate pathological response and improve local
control (LC) and possibly OS. Indeed, pre-operative CT/RT has
been reported to achieve very encouraging results in terms of
extent of LC and OS,2–7 albeit concerns have been raised about
the potential increase of the rate and the severity of treatment-
related side effects.8,9
Results of the GYNECO 02 trial seemed to suggest that comple-
tion hysterectomy had no therapeutic impact in patients with
clinical and radiological complete response after chemoradiation,
although this conclusion was limited by the lack of power.10 On
the other hand, the Phase III study by Cetina et al11 demonstrated
that CT/RT followed by RS is not superior to exclusive CT/RT,
although the results are feasible and safe. Reasonably, both
approaches have associated toxicity problems at similar rates, al-
though these are attributed to different mechanisms.12
Surgery for pathological response to treatment might have clinically
relevant implications for deﬁnition of risk pattern of recurrence,
individualized patient counselling and choice to administer adju-
vant treatment.12,13 Based on the close relationship between path-
ological response to neoadjuvant therapies and outcome, several
efforts have been made in the last decade to modify dose and
fractionation of cisplatin-based chemoradiation, as well as treat-
ment time length or irradiated volumes.14,15
In order to improve LC by reducing the rate of regional failures
at para-aortic lymph node level as well as in-ﬁeld recurrences,
a Phase I study [large ﬁeld adjuvant radiotherapy in advanced
cervical carcinoma (LARA-CC)-1 study] was set up by our
Radiation Oncologists and Gynecologists group to investigate
a regimen based on gross tumour volume (GTV)-accelerated
fractionation and lymph node extended-ﬁeld (LNEF) irradiation
followed by RS.16 The total dose of 45Gy (2.25Gy/fraction) to
macroscopic tumour and 40Gy (2Gy/fraction) to lymph node
stations was established as the recommended dose for the fol-
lowing study.16,17 Indeed, LARA-CC-1 Phase II trial demon-
strated that, at the recommended dose, complete pathological
response (primary cervix and the nodes as well) to treatment
was achieved in 38.6% of cases, a ﬁgure in line with previously
reported results, but susceptible to further improvement
through more advanced treatment delivery techniques. In this
context, intensity-modulated radiotherapy (IMRT), where ﬂu-
ence of each beam is intentionally altered by the summation of
hundreds of beamlets, could represent a valid strategy to satisfy
clinical goals of target and normal tissue doses. IMRT has been
shown to decrease the acute and late gastrointestinal (GI) tox-
icities owing to the conformality of dose distribution, conﬁning
the high-dose portions of radiation ﬁelds and reducing the
absorbed dose in critical organs.18 Promising results have been
achieved by IMRT in patients with LACC in the intact disease
setting and post-operatively.19 Furthermore, conventional IMRT
techniques allow the simultaneous delivery of different doses to
different target volumes within a single fraction. This strategy is
known as simultaneous integrated boost (SIB) technique (SIB-
IMRT); it was introduced in several anatomical sites and is
used to increase the fraction dose to the boost volume. SIB-
IMRT keeps the dose to the elective volume at a low level and
provides clinical and dosimetric advantages.20,21
To test the SIB-IMRT approach in patients with LACC, a Phase
I–II study (LARA-CC-2) was launched in our radiotherapy unit
(Catholic University, Campobasso, Italy) with the aim to in-
vestigate the feasibility and determine the recommended pre-
operative IMRT dose of LNEF chemoradiation along with SIB
dose escalation. Toxicity and outcome results are reported.
METHODS AND MATERIALS
Patient characteristics
Patients with The International Federation of Gynecology and
Obstetrics (FIGO) stage IB2–IVA and histological proven invasive
carcinoma of the cervix were eligible, regardless of pelvic lymph
node status (Table 1). CT chest scan and abdominopelvic MRI
were required for staging. Positron emission tomography (PET)-
CT scan was not mandatory according to the study design.
Patients were clinically staged on the basis of the pre-treatment
workup by a multidisciplinary team including radiation oncolo-
gists, gynaecological oncologists and radiologists dedicated to
gynaecological malignancies. Chemotherapy, abdominopelvic ra-
diotherapy or any cancer treatment within the previous 3 years
were considered as exclusion criteria.
Study design and end points
This was a prospective Phase I–II dose-escalation study (LARA-
CC-2) approved by our institutional review board. All patients
were required to provide a written informed consent agreeing to
Table 1. Patient characteristics
Patient characteristics Number (%)
Whole series 19
Age, years, median (range) 46 (30–73)
FIGO stage
IB2 3 (15.8)
IIB 10 (52.6)
IIIA 4 (21.1)
IIIB 2 (10.5)
Histotype
Squamous 17 (89.5)
Adenocarcinoma 2 (10.5)
Tumour volume (cm)
,4 1 (5.3)
$4 18 (94.7)
Grade
1–2 5 (26.3)
3 11 (57.9)
Not speciﬁed 3 (15.8)
Pelvic lymph node statusa
Negative 10 (52.6)
Positive 9 (47.4)
FIGO, The International Federation of Gynecology and Obstetrics.
aAt MRI.
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be submitted to all the procedures described and for their data
to be collected. Primary end point was determination of the
“recommended dose”, otherwise known as the “maximally tol-
erated dose” (MTD). The “recommended Phase II dose” was
deﬁned as the lower dose level below the “highest administered
dose”, which corresponds to the dose associated with dose-
limiting toxicity (DLT) in at least one-third of patients. Any
treatment-related non-haematological adverse effects rated as
grade $3 or any haematological toxicity rated as grade $4 by
the Radiation Therapy Oncology Group acute (RTOG)/
European Organisation for Research and Treatment of Cancer
scale were deﬁned as DLTs. If the DLT was not observed in the
three patients at a set dose level, the trial proceeded to the next
one, provided that 3 months of follow-up had occurred after the
treatment for the third patient of the cohort. If a DLT occurred
in one of the three patients at a given dose level, treatment of up
to three additional patients at this dose level was required. If the
DLT occurred in more than one patient of the three patients’
cohort, dose escalation would stop, and the dose level below that
would be considered as the MTD. As well, if a DLT occurred in
two or more patients of the expanded six-patient cohort, dose
escalation would stop, and the dose level below that would be
considered as the MTD. Lastly, if a DLToccurred in less than two
patients of the expanded six patient cohort, the trial proceeded
to the next dose level.
Patients were enrolled in three consecutive boost dose levels, as
reported in Table 2. Treatment was discontinued in patients with
grade $3 non-haematological toxicity until grade 2 toxicity
was resumed.
Secondary end points included the evaluation of pathologically
assessed complete response (pCR), LC, disease-free survival
(DFS) and OS.
Radiotherapy treatment planning
All patients underwent CT-based planning in a prone position
using an up–down table device to displace small bowel volume
from the treatment ﬁeld. Patients with LACC received bowel
preparation before simulation, and an empty rectum was re-
quired before CT simulation. To limit interfraction or intra-
fraction variability, a bladder-ﬁlling protocol (consisting of
asking patients to void, drink 1 l of water 30–45 min before
treatment and hold urine) was followed during CT simulation
and subsequently before each treatment. After the administra-
tion of oral contrast medium, 4-mm CT images were obtained
from the upper border of the T12 vertebral body to 3 cm below
the ischial tuberosity.
Three clinical target volumes (CTV3, CTV2 and CTV1) were
identiﬁed and contoured on CT simulation scan according to
the guidelines by Taylor et al22 and Lim et al23 (Figure 1). CTV3
included primary tumour and positive lymph nodes (GTV),
vagina (entire or upper half according to involvement), uterus,
parametria, ovaries, obturator, external iliac, internal iliac, pre-
sacral (cranially to S2–S3 vertebrae) and common iliac lymph
nodes (pelvic Level III) up to its apex in front of L3 vertebra.24
The CTV3 upper ﬁeld limit was chosen with the aim to irradiate
lymph node areas normally excluded from the standard pelvic
treatment yet potential sites of micrometastases.16,25,26 CTV2
was considered as CTV3 excluding pelvic Level III; therefore, the
CTV2 upper border of the ﬁeld was kept at L4–L5 junction.
CTV1 corresponded to GTV plus 1.5-cm margin into the uterus
and included the positive lymph nodes, if present.
Planning target volumes (PTV3, PTV2 and PTV1) were deﬁned
as clinical target volumes (CTV3, CTV2 and CTV1) plus 8mm.
Organs at risk, including the small bowel, rectum, bladder and
femoral heads, were also contoured. Individual loops of small
bowel were contoured separately from the axial slice situated
1 cm above the most superior slice containing the PTV and
continued to its most inferior extent in the pelvis. The rectum
being an organ was contoured as a solid continuous structure
and was deﬁned from the level of the sigmoid ﬂexure to the
anus. The bladder was similarly contoured as a solid continuous
structure, whereas the bone marrow was not contoured.
The extended-ﬁeld SIB-IMRT technique was employed in all
patients. Three dose levels were planned: Level 1 (PTV3: 40/2Gy;
PTV2: 40/2Gy; PTV1: 45/2.25Gy), Level 2 (PTV3: 40/2Gy;
PTV2: 45/2.25Gy; PTV1: 45/2.25Gy) and Level 3 (PTV3: 40/
2Gy; PTV2: 45/2.25Gy; PTV1: 50/2.5Gy). All treatments were
delivered in 20 fractions. The PTV1 dose of 50Gy in 2.5Gy/
fraction was selected at the beginning of the study as the highest
dose level owing to small bowel tolerance, being the equivalent
dose in 2Gy/fraction for late effects (a/b ratio: 3) equivalent to
55Gy (Table 2).27 Dose speciﬁcations and nomenclature were
Table 2. Dose cohorts
Number of planned patients Number of treated patients Dose level
Dose (Gy)/fraction
PTV3a PTV2b PTV1c
3 6 I 40/2 40/2 45/2.25 (47.25)d
3 7 II 40/2 45/2.25 (47.25)d 45/2.25 (47.25)d
3 6 III 40/2 45/2.25 (47.25)d 50/2.50 (55.0)d
EQD2, equivalent dose in 2Gy/fraction; PTV, planning target volume.
aPTV3: pelvic lymph nodes up to L3 plus margin.
bPTV2: pelvic lymph nodes up to L5 plus margin.
cPTV1: macroscopic disease plus margin.
dEQD2 for late effects (a/b ratio: 3).
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according to the International Commision on Radiation Units
and Measurements report 83. Dose–volume prescriptions are
shown in Table 2. Doses were converted into their radiobiological
equivalence to determine the tolerances. Target planning con-
straints used were reported in Table 3. All IMRT plans consisted
of seven co-planar equispaced ﬁelds with 6-MV photons. All plans
were generated with Oncentra® MasterPlan treatment planning
system (Oncentra Masterplan) and delivered by an Elekta Precise
Linear Accelerator (Elekta Ltd, Crawley, UK).
Owing to the complexity of treatment, all plans underwent pre-
treatment veriﬁcation. The delivered doses were measured using
the seven 29 ion chamber array.28,29 PTW VeriSoft® software
v. 4.0 (VeriSoft software; PTW, Freiburg, Germany) was used to
carry out a comparison of measured vs calculated dose dis-
tributions. The gamma index evaluation was employed. If the
percentage of points fulﬁlling gamma index criteria exceeded
95% (3% for dose criterion and 3mm for the distance to
agreement criterion), the pre-treatment dosimetry was consid-
ered optimal. For quality assurance through treatment planning
and delivery, two independent checks (IC1 and IC2) were per-
formed by medical and physics staff;30 daily set-up re-
producibility was checked.31 Portal images before irradiation
were acquired on virtual orthogonal beams and deviations
.3mm in the isocentre position were immediately corrected as
previously described.31
Chemotherapy
In the ﬁrst and last weeks of radiotherapy, cisplatin (20mgm22,
2-h intravenous infusion, Days 1–4) and 5-ﬂuorouracil
(1000mgm22, 24-h continuous intravenous infusion, Days 1–4)
were administered. In case of relapse/progression of disease, patients
were considered for salvage treatment on a case-by-case basis.
Surgery
4–6 weeks after completion of CT/RT, objective response to
treatment was evaluated according to response evaluation criteria
in solid tumour criteria; patients achieving response to treatment
were triaged to radical hysterectomy (RH) according to Querleu
and Morrow32 and pelvic 6 aortic lymphadenectomy within 6–
8 weeks from the completion of CT/RT. Aortic lymphadenectomy
was performed in case of (i) positive pelvic lymph nodes at frozen
section analysis routinely performed during completion surgery,
(ii) positive pelvic lymph nodes at imaging within initial staging
workup and (iii) intraoperatively assessed suspicious aortic lymph
nodes. In the case of stable disease or progression rescue, che-
motherapy or chemoradiation was allowed.
Pathological response to treatment was evaluated based on
the examination of uterus, vaginal cuff, parametrium, pelvic
and aortic lymph nodes: residual disease at any site was
expressed in millimetres, and response was deﬁned as com-
plete [absence of any residual tumour after treatment at any
site level: pathological complete response (pCR)], micro-
scopic [persistent tumour foci of #3mm maximum di-
mension microscopic pathological response (microPR)] and
macroscopic (persistent tumour foci of .3mm maximum
dimension).8
Toxicity assessment
Radiation-related toxicity was assessed prospectively according to
the RTOG criteria. Acute adverse events were deﬁned as those
adverse events occurring from Day 1, or commencement of ra-
diation therapy, up to Day 90. Bowel, bladder, ureteral or vascular
injuries, as well as estimated blood loss .500ml, were deﬁned as
operative complications. Any adverse events occurring within or
Figure 1. Planning target volumes [PTV3 (red isodose), PTV2 (yellow isodose), PTV1 (green isodose)] are shown on orthogonal
digital reconstructed radiographs. For colour image see online.
Table 3. Planning constraints
Region of interest Constraint
PTV
V95%. 95%
V107%, 2%
Small bowel V15, 120 cm
3
Rectum V50, 50%
Femoral heads V50, 10%
PTV, planning target volume; V15, volume receiving 15 Gy; V50, volume
receiving 50Gy; V95%, volume receiving 95% of the prescribed dose;
V107%, volume receiving 107% of the prescribed dose.
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after 30 days from surgery were deﬁned as early and long-term
post-operative complications, respectively. Surgical morbidity was
classiﬁed according to the Chassagne grading system. Patients
underwent quarterly follow-up for the ﬁrst 2 years and half-yearly
thereafter. Even in the case of documented relapse or disease
progression, late toxicities were continuously monitored.
Statistical analyses
Medians and life tables were computed using the product limit
estimate by Kaplan–Meier method, and the log-rank test was
used to assess the statistical signiﬁcance. LC was calculated
from the date of surgery to the date of the inside ﬁeld relapse/
progression of disease or the date last seen. Likewise, DFS was
calculated from the date of surgery to the date of relapse or the
date of the last follow-up; OS was calculated from the date of
diagnosis to the date of death or the date of the last follow-up.
Statistical analyses were performed using Systat v. 10.2 (Systat
for Windows, Software Inc. 2002, San Jose, CA).
RESULTS
Patient population
This study included 19 consecutive patients with LACC in dose
cohorts. Population characteristics and dose level details are
reported in Tables 1 and 2, respectively. Nearly 60% (11 of 19)
had a PET-CT scan in their workup, although PET-CT was not
mandatory, according to the study design.
Compliance and toxicity
At Level I, one patient out of three had GI grade 3 toxicity (emesis,
nausea, diarrhoea); therefore, additional three patients were
recruited, and all of them completed CT/RT without any DLT. All
Level I patients (n5 6) completed CT/RT and underwent RS.
Based on these ﬁndings, dose Level II was opened for accrual: one
out of three patients developed grade 3 proctocolitis with emesis,
nausea, diarrhoea and was successfully treated by parenteral
medical therapy. This patient also suffered from a herpes zoster
virus infection during the time interval between CT/RT
Table 4. Acute toxicity after chemoradiationa
Toxicity Grade
Level I (n5 6),
PTV35 40Gy,
PTV25 40Gy,
PTV15 45Gy
Level II (n5 7),
PTV35 40Gy,
PTV25 45Gy,
PTV15 45Gy
Level III, (n5 6),
PTV35 40Gy,
PTV25 45Gy,
PTV15 50Gy
Whole
series
(n5 19)
Number of cases Number of cases Number of cases
Number of
cases (%)
Lower
gastrointestinal
0 1 0 0 1 (5.3)
1 2 0 1 3 (15.8)
2 2 6 3 11 (57.9)
3 1 1 2 4 (21.1)
Upper
gastrointestinal
0 6 6 5 17 (89.5)
1 0 0 0 0
2 0 1 1 2 (10.5)
3 0 0 0 0
Genitourinary
0 1 3 1 5 (26.3)
1 3 4 2 9 (47.4)
2 2 0 3 2 (10.5)
3 0 0 0 0
Skin
0 2 1 2 5 (26.3)
1 1 4 2 7 (36.8)
2 3 2 2 7 (36.8)
3 0 0 0 0
Haematological
0 3 2 3 8 (42.1)
1 1 0 0 1 (5.3)
2 1 2 1 4 (21.1)
3 1 3 1 5 (26.3)
4 0 0 1 1 (5.3)
PTV, planning target volume.
aThe two patients with severe genitourinary toxicities recorded in the perioperative period are described in the text; acute toxicity was graded
according to the Radiation Therapy Oncology Group acute criteria. Number of patients are reported per level and in the whole series.
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completion and RS. Level II cohort was thus expanded to include
three patients plus an additional one who was treated while
monitoring of toxicity was ongoing in the preceding three patients.
All Level II patients (n5 7) completed CT/RT and were triaged to
RS. At level III, one patient presented grade 3 GI toxicity (emesis,
nausea, diarrhoea) requiring intravenous ﬂuid intake until resolu-
tion, thus leading to the expansion of dose Level III (n5 6). Since
the second patient developed grade 3 GI, the study was closed, and
the recommended dose was established as that corresponding to
dose Level II. Details about the pattern and severity of acute toxicity
are presented in Table 4. The predominant DLTs were GI. Grade
$3 lower GI toxicity occurred in 21% of patients and consisted
mainly of dehydration secondary to nausea, vomiting or diarrhoea,
which required intravenous ﬂuid administration. No patients
presented grade $3 genitourinary (GU) or skin acute toxicity.
Grade $3 haematological toxicity occurred in 31.5% of patients,
and one dose-limiting leukopenia (grade 4) was recorded in a
patient affected also by grade 3 GI toxicity. All reported toxicities
occurred within 10–20 days after the end of chemoradiation.
As far as intraoperative complications are concerned, we docu-
mented only one bladder injury (5.3%) in a patient treated at the
dose Level III; the lesion was managed intraoperatively without
major intervention.
In the post-operative period, 2 patients (10.5%) experienced the
following grade 3 GU complications: one patient had fever on
the fourth day after surgery, and abdominal CT scan showed
three lymphocysts, of which the largest one (maximum axial
diameters5 60325mm) was located in the right pelvis and
surrounded by the iliopsoas muscle, the external iliac vessels and
laterally by the right side wall of the bladder. Since the patient was
complaining about chronic abdominal pain, the largest lym-
phocyst was removed through minilaparotomy 5 months later.
9 months after surgery, the patient developed grade 1 bilateral
ureteral dilatation with normal renal function, in the absence of
signs of disease up to 26 months since diagnosis.
The second patient, suffered from ureteral intra-abdominal
leakage and underwent laparotomy with permanent percutane-
ous nephrostomy which permitted subsequent normal renal
function (grade 3). Also in this case, there was no sign of disease
after 14 months from diagnosis.
Concerning long-term toxicity, the actuarial 2-year ($grade 2) GU
toxicity-free survival was 88.8%; neither grade $2 GI complications
nor skin or mucosal toxicities were observed (data not shown).
Treatment planning details
According to dosimetric constraints, target coverage was met in all
patients. Planning constraints for normal tissues were always
respected with the exception of small bowel: only two patients
respected V15,120 cm
3 constraint; on the contrary, 89.5% (17 of
19) of patients largely exceeded the V15 ,120 cm
3 constraint
(median value5268.9 cm3, range596–481 cm3). Three of the four
patients presenting severe GI toxicity did not meet the quantitive
analysis of normal tissue effects in the clinic (QUANTEC) small
bowel constraint V15 ,120 cm
3 (Pearson x2: p5 0.440).
Pathological response
RH was possible in all patients; laparotomic approach was per-
formed in 68.4% of cases. Systematic pelvic lymphadenectomy was
performed in all patients with a median number of removed lymph
nodes of 27 (range 5 15–57). 11 (57.9%) patients were also sub-
mitted to aortic lymphadenectomy (median number of removed
lymph nodes 5 8, range 5 3–54).
Pathological complete response (CR) rate combining both pCR
and micro-pPR rates was 63.1%, with 6 (31.6%) patients
showing pCR to treatment and 6 (31.6%) showing microPR.
Macroscopic response was observed in 7 (36.8%) cases.
Outcomes and survival
As of October 2014, median follow-up period was 24 months
(range 5 9–60 months). Relapse/progression of disease was
observed in 4 of 19 patients (21.1%): in particular, 2 cases
(10.5%) developed extrapelvic recurrence; 1 patient had lung
metastasis and underwent resection and subsequently developed
brain metastases which were irradiated; and 1 patient had me-
diastinal and supraclavicular lymph node relapse and received
rescue chemotherapy. Finally, two patients (10.5%) developed
mixed recurrences (local recurrence and distant metastases).
There was no case of recurrence/progression occurring exclu-
sively in the pelvic region.
The 2-year LC was 89.5% (median LC: not reached), while the
2-year DFS was 82.0% (median DFS: not reached). Death due to
disease was recorded in 2 of 19 patients (10.5%), and the 2-year
OS was 88.8% (median OS: not reached).
DISCUSSION
The working hypothesis supporting the present study was
mainly based on our previous experience with pre-operative
GTV-accelerated fractionation and LNEF irradiation (up to L3
vertebra) delivered by the three-dimensional (3D) technique.16,17
Despite the dose escalation, studies16,17 proved the safety and
potential efﬁcacy of 45Gy concomitant boost plus 40Gy enlarged
ﬁeld chemoradiation in patients with LACC. However, the Phase
II study failed to show an increase in the rate of pCR to treatment.
With the aim to deliver over a short time interval, a higher ra-
diotherapy dose at sites of macroscopic disease without increasing
the rate/severity of damage to normal tissues associated with the
3D approach, escalating doses of SIB-IMRT were investigated in
the present study. This analysis represents, to our knowledge, the
ﬁrst evaluation of LNEF-SIB-IMRT as pre-operative treatment of
patients with LACC.
Results from the current Phase I study established the dose of
45Gy to macroscopic tumour, positive lymph nodes, common
iliac lymph nodes up to the cranial margin of L5 vertebra, and
40Gy to common iliac lymph nodes in front of L3 up to its apex,
as the recommended dose for further evaluation.
Contrary to results expected from the use of IMRT techniques in
the exclusive chemoradiation as well as adjuvant setting,19,33–35
we could not escalate the dose at levels higher than those reached
with the 3D approach; indeed, acute GI toxicity represented the
BJR Macchia et al
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major limitation to dose escalation and were documented at rates
similar to those observed with the 3D technique in the same
clinical setting.16,17 Reasonable caution has to be taken in inter-
preting these data given the small sample size of current series
which included a slightly higher fraction of patients bearing pelvic
lymph node involvement at imaging, a condition which could
have implied the requirement of higher dose target volume and
consequently larger small bowel irradiation.
In this context, it has also to be underlined that, even though
a controlled ﬁlling protocol was applied and daily portals enclosed
in the plan have been performed before treatment, no daily cone
beam image guidance was available, thus possibly determining an
excessive amount of normal tissue falling into the high-dose areas
of treatment as the tumours regressed over the course of treat-
ment. In addition, although carefully educated, we cannot be
certain that the patients have respected the daily controlled ﬁlling
protocol for bladder and rectum. As pelvic organ motion seems
to be patient speciﬁc, individualized PTV margins and adaptive
image-guided radiotherapy (IGRT) strategies have also been rec-
ommended to ensure target volume coverage while increasing
OAR sparing. Although these strategies are promising, they need
signiﬁcant validation before they can be adopted into clinical
practice. In a very recent article by a French group,35 authors
delivered 50Gy in the PTV1 and 60Gy in the PTV2 simulta-
neously in 28 fractions (5 fractions a week). Indeed, the volumes
irradiated were considerably smaller than ours; in particular, our
boost volume corresponded to GTV plus 1.5-cm margin into the
uterus and included the positive lymph nodes, if present, while
Mouttet-Audouard et al35 boosted on GTV plus a 4-mm margin.
Moreover, PTV margin was larger in our experience than in the
French study (8 vs 3mm), resulting in a larger amount of normal
tissue falling into the high-dose areas of treatment.
As far as perioperative toxicity is concerned, we documented only
two cases of post-operative urinary complications with an overall
rate of 10.5% in keeping with the corresponding ﬁgure (29%,
mostly urinary) obtained in the 3D dose escalation as well as
Phase II study in a similar setting.16,17 Whether this observation
could be ascribed to a lower impact of IMRT on tissue tropism
with subsequent easier surgical procedures remains difﬁcult to
be ascertained: in fact, the relevance of surgeons’ skilfulness and
learning curve in RS cannot be underestimated.
Conversely, our late toxicity results are hardly comparable to
those reported in the setting of intact disease not only because
of the evident differences of study design and population, but
extension of volumes encompassing both positive pelvic
lymph nodes and primary tumour at the highest dose, and
upper limit of the irradiation ﬁeld at cranial margin of the
third lumbar vertebra, could imply a more than standard ir-
radiation of the small intestine. It has to be underlined that the
small bowel constraint normally reported in literature (i.e. the
120 cm3 volume of small bowel receiving .15 Gy, in order to
minimize severe acute toxicity)36 remained unsatisﬁed in
89.4% of cases.
Finally, the treatment time (4 weeks) could have impaired the
adequate small bowel repopulation, thus leading to a negative
impact on damaged tissue repair. As far as clinical outcome is
concerned, we reported a rate of pCR to treatment of 63.1% and
a 2-year LC rate of 89%, which is systematic with previously
reported data.8,16,17
In conclusion, SIB-IMRT, as delivered, was unable to safely escalate
dose beyond those achieved with 3D conformal radiotherapy given
acute GI toxicity; therefore, we established the dose of 45Gy to
macroscopic tumour, positive lymph nodes, common iliac lymph
nodes up to the cranial margin of L5 vertebra, and 40Gy to
common iliac lymph nodes in front of L3 up to its apex, as the
recommended doses for further evaluation of IMRT extended-ﬁeld
chemoradiation plus simultaneous integrated boost in the pre-
operative treatment of patients with LACC.
Since interfractional and intrafractional shifts, possibility of
signiﬁcant tumour regression during treatment, economic
impact of increased planning and technological requirement
can represent potential concerns in IMRT approach to patients
with LACC, further studies with larger sample size, longer
follow-up and image guidance are needed. A cautious approach
to this kind of treatment in the absence of adaptive IGRT
strategies needs to be validated before they can be adopted into
clinical practice.
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